Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310431 | 1.00 | PDE5A (0.36) | PDE5APRKCZLMNAESR2RIPK1 | |
| SCHEMBL839486 | 1.00 | PDE5A (0.36) | PDE5APRKCZLMNAESR2RIPK1 | |
| SCHEMBL840063 | 0.82 | KCNH2 (0.48) | LMNAKDM4EALDH1A1MAOB | |
| SCHEMBL310889 | 0.82 | KCNH2 (0.48) | LMNAKDM4EALDH1A1MAOB | |
| SCHEMBL2831517 | 0.80 | ESR2 (0.39) | PDE5ALMNAESR2ESR1KDM4E | |
| SCHEMBL4765128 | 0.80 | ESR2 (0.39) | PDE5ALMNAESR2ESR1KDM4E | |
| SCHEMBL839659 | 0.78 | KCNH2 (0.56) | MAOB | |
| SCHEMBL840054 | 0.78 | KCNH2 (0.56) | MAOB | |
| SCHEMBL310423 | 0.78 | KCNH2 (0.56) | MAOB | |
| SCHEMBL1104538 | 0.72 | GPR119 (0.37) | PDE5ALMNAESR2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153681-B2 | Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8143306-B2 | Methods of treating bipolar disorders | Convergence Pharmaceuticals Limited (GB) | 2012-03-27 | — | — | US | disclosed |
| US-20110098335-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098335-A1 | NOVEL COMPOUNDS | SCN1A, SCN1B, SCNN1B | PDE5A 625/4885PRKCZ 2115/4885LMNA 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.